None listed
Conditions
Brief summary
This study is examining two biopsy regimens for surveillance follow-up in patients where Barrett’s oesophagus with dysplasia or cancer has been eradicated. Who is it for? You may be eligible for this study if you have undergone successful endoscopic Barrett's oesophagus and/or oesophageal adenocarcinoma eradication and are currently having follow-up surveillance endoscopies. Study details All participants will undergo surveillance endoscope and biopsy as per their current standard treatment. The study personnel will record the time taken to take samples and perform economic analysis. Please note there is no additional testing or input required by participants in this study beyond participating in their routine care. It is hoped this research will demonstrate that a reduced test biopsy regimen is more cost- and time-efficient than the standard biopsy regimen without reducing the surveillance quality.
Interventions
We will be comparing two groups of outcomes in the same patient (ie. they become their own control group) - we will be practicing standard care with regards to endoscopic follow up of eradicated dysplastic Barrett's oesophagus and intramucosal oesophageal adenocarcima. This involves taking targeted biopsies of endoscopically abnormal areas (eg. nodules or ulcers) as well as biopsies from the gastric cardia and along the affected portion of the oesophagus in a systematic manner; four quadrant bio
We will be comparing two groups of outcomes in the same patient (ie. they become their own control group) - we will be practicing standard care with regards to endoscopic follow up of eradicated dysplastic Barrett's oesophagus and intramucosal oesophageal adenocarcima. This involves taking targeted biopsies of endoscopically abnormal areas (eg. nodules or ulcers) as well as biopsies from the gastric cardia and along the affected portion of the oesophagus in a systematic manner; four quadrant biopsies every 1cm will be taken as per the Seattle protocol, which is current standard of care. We will be recording the time and resources required for surveillance biopsies as well as the results of these to determine whether omitting these surveillance biopsies as per Seattle protocol in the future would be non-inferior to current standard of practice with regards to histology results and patient outcome; this would significantly save on time and costs associated with the process. Therefore, the two groups will be as follows: Control - gastric cardia, targeted and surveillance biopsies Test - gastric cardia and surveillance biopsies only
Sponsors
Princess Alexandra Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult patients who have undergone successful Barrett's oesophagus eradication who are currently having follow-up surveillance endoscopies
Exclusion criteria
patients with dysplastic Barrett's that have not achieved complete eradication of intestinal metaplasia.
Outcome results
None listed